Verónica Galván

PLoS ONE · 2010

⊕ Open access · CC-BY

Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease

▲ 1,026

Neuroscience · 2012

◌ Citation only

Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice

▲ 223

American Journal of Physiology-Heart and Circulatory Physiology · 2017

⊕ Open access · OA

Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer’s disease and vascular cognitive impairment

▲ 140

Aging Cell · 2015

⊕ Open access · CC-BY

Chronic <scp>mTOR</scp> inhibition in mice with rapamycin alters <scp>T</scp> , <scp>B</scp> , myeloid, and innate lymphoid cells and gut flora and prolongs life of immune‐deficient mice

▲ 127

Experimental Gerontology · 2014

⊕ Open access · CC-BY

How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story

▲ 124

Frontiers in Molecular Neuroscience · 2014

⊕ Open access · CC-BY

Divergent tissue and sex effects of rapamycin on the proteasome-chaperone network of old mice

▲ 95

Aging Cell · 2019

⊕ Open access · CC-BY

mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging

▲ 77

Journal of Neuroscience · 2021

⊕ Open access · OA

mTOR Attenuation with Rapamycin Reverses Neurovascular Uncoupling and Memory Deficits in Mice Modeling Alzheimer's Disease

▲ 61

Gerontology · 2018

⊕ Open access · OA

A Perfect sTORm: The Role of the Mammalian Target of Rapamycin (mTOR) in Cerebrovascular Dysfunction of Alzheimer's Disease: A Mini-Review

▲ 41

2020

⊕ Open access · CC-BY

Editor's evaluation: In vivo transcriptomic profiling using cell encapsulation identifies effector pathways of systemic aging

▲ 0